Hester Biosciences

Hester Biosciences Net Margin

The Net Profit Margin of Hester Biosciences (HESTERBIO.NS) as of Nov 19, 2026 is 16.73 %. In the previous year, Net Profit Margin was 8.84 % — a change of 89.33% (higher).

Net Margin

16.73 %

YoY

89.33%

Last updated:

Net Profit Margin of Hester Biosciences is 2026 16.73 % . Net Profit Margin of Hester Biosciences was 2025 8.84 % . It decreases by 89.33% higher compared to the previous year.

For Hester Biosciences, the net margin of 16.7% is broadly stable versus 16.7% a few years ago.

The Hester Biosciences Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
23.34 INR
Jan 1, 2020
15.92 INR
Jan 1, 2021
16.06 INR
Jan 1, 2022
16.73 INR
Jan 1, 2023
10.01 INR
Jan 1, 2024
6.20 INR
Jan 1, 2025
8.84 INR
Jan 1, 2026
16.73 INR
The Hester Biosciences Net Margin history
YEARNet MarginYoY
16.73 %+89.33%
8.84 %+42.46%
6.20 %-38.02%
10.01 %-40.19%
16.73 %+4.16%
16.06 %+0.92%
15.92 %-31.81%
23.34 %+23.86%
18.85 %-1.05%
19.05 %+1.77%
18.72 %+36.08%
13.75 %+0.46%
13.69 %+9,526.77%
0.14 %-9.78%
0.16 %-12.89%
0.18 %+12.59%
0.16 %+2.36%
0.16 %-27.21%
0.22 %-8.58%
0.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hester Biosciences Stock analysis

What does Hester Biosciences do? Hester Biosciences Ltd. generates revenue through its four operational segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The company sells poultry vaccines such as Gumboro I, Inactivated ND IB, and Live H120, alongside animal health products including Goat Pox Vaccine and PPR Vaccine - Nigerian 75/1. Petcare offerings like Cefshot Tazo Injection and Hestacef CV target veterinary clinics and pet owners. The firm serves agricultural businesses, veterinary practitioners, and pet care providers across India, with its products distributed through trade channels and direct sales to livestock farmers and clinics. Animal Healthcare segment focuses on livestock protection with vaccines for goats and cattle, while Poultry Healthcare provides specialized immunizations for commercial poultry farms. Diagnostic laboratory services complement the product portfolio, supporting livestock health management. The company's product range caters to both large-scale farming operations and smaller veterinary practices, ensuring consistent demand across its target markets. Revenue streams are derived from direct sales to farmers and veterinary clinics, as well as trade distribution networks. The firm's portfolio includes thermostable vaccines for poultry, such as Thermostable ND, which appeals to commercial poultry producers seeking reliable disease prevention solutions. Petcare products like Hestaflam Tablet are marketed to pet owners and veterinary hospitals, expanding the company's reach beyond traditional agricultural sectors. Hester Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hester Biosciences stock

Net Profit Margin of Hester Biosciences is 16.73 % in 2026.

Net Profit Margin of Hester Biosciences changed from 8.84 % to 16.73 %, representing a 89.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Hester Biosciences since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Hester Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Hester Biosciences

All Key Metrics — Hester Biosciences